Myovant Sciences

$22.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.49 (-6.09%) As of 6:26 PM UTC today

Why Robinhood?

You can buy or sell MYOV and other stocks, options, and ETFs commission-free!

About MYOV

Myovant Sciences Ltd., also called Myovant Sciences, is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. The listed name for MYOV is Myovant Sciences Ltd.

CEO

Lynn Seely

Employees

214

Headquarters

London, Greater London

Founded

2016

Market Cap

2.09B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

718.30K

High Today

$24.45

Low Today

$22.70

Open Price

$24.30

Volume

750.24K

52 Week High

$25.03

52 Week Low

$5.98

Collections

Analyst Ratings

88%

of 8 ratings

Buy

88%

Hold

13%

Sell

MYOV Earnings

-$1.07

-$0.71

-$0.36

$0.00

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Estimated

— per share

Actual

Expected Feb 10, Pre-Market